New horizons for focused ultrasound (FUS) - therapeutic applications in neurodegenerative diseases.
Authors: Miller DB, O'Callaghan JP
Access to the CNS and delivery of therapeutics across the blood-brain barrier remains a challenge for most treatments of major neurological diseases such as AD or PD. Focused ultrasound represents a potential approach for overcoming these barriers to treating AD and PD and perhaps other neurological diseases. Ultrasound (US) is best known for its imaging capabilities of organs in the periphery, but various arrangements of the transducers producing the acoustic signal allow the energy to be precisely focused (F) within the skull. Using FUS in combination with MRI and contrast agents further enhances accuracy by providing clear information on location. Varying the acoustic power allows FUS to be used in applications ranging from imaging, stimulation of brain circuits, to ablation of tissue. In several transgenic mouse models of AD, the use of FUS with microbubbles reduces plaque load and improves cognition and suggests the need to investigate this technology for plaque removal in AD. In PD, FUS is being explored as a way to non-invasively ablate the brain areas responsible for the tremor and dyskinesia associated with the disease, but has yet to be utilized for non-invasive delivery of putative therapeutics. The FUS approach also greatly increases the range of possible CNS therapeutics as it overcomes the issues of BBB penetration. In this review we discuss how the characteristics and various applications of FUS may advance the therapeutics available for treating or preventing neurodegenerative disorders with an emphasis on treating AD and PD.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To review how focused ultrasound can overcome the blood–brain barrier to enable delivery and application of therapeutics for treating or preventing Alzheimer's and Parkinson's disease.
Animal model / Human subject
Mouse (transgenic mouse models of Alzheimer's disease), strain: not specified, age: not specified, sex: not specified
Disease model
Alzheimer's disease, Parkinson's disease
MRI or image guidance method
MRI-guided focused ultrasound with contrast agents
Cargo name and characteristics
Antibodies (protein biologics), gene therapies (genetic cargo/viral vectors such as AAV implied), growth factors (protein biologics), and stem cells (cellular therapy)
Outcomes and Safety
Summary of Outcomes
Focused ultrasound (FUS), particularly when combined with microbubbles and MRI guidance, opened the BBB, reduced amyloid plaque load and improved cognition in transgenic Alzheimer’s mouse models; in Parkinson’s disease FUS has been effective as a noninvasive ablation approach to reduce tremor/dyskinesia. Successful FUS parameters reported include FUS + microbubbles for BBB opening and therapeutic delivery, MRI-guided targeting with contrast agents, and modulation of acoustic power to achieve imaging, neuromodulation, or tissue ablation.
Safety-related matter
The provided text does not mention any safety concerns or adverse effects related to focused ultrasound; no adverse events are reported in this excerpt.
Brain Region
Ultrasound Parameters
Focal Characteristics
focal depth: None; focal length: None; aperture size: None
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search